To my dear wife, Anu, and to my lovely kids, Shravya and Saureesh

Aparasu

To my wife and partner, Sandy, and to my teacher, mentor, and friend, Lon Larson

Bentley
CONTENTS

Preface xv
Foreword xix
Acknowledgements xxi
About the Editors xxiii
Contributors xxv
Reviewers xxix

Section 1 Principles of Clinical Research 1
Chapter 1 The Scientific Approach to Research and Practice 2
by Rajender R. Aparasu, MPharm, PhD, FAPhA

Introduction 3
Biomedical Research 3
Evolving Research Paradigms 5
Determinants of Scientific Methodology 6
Process of Scientific Inquiry 6
Evidence-Based Medicine 10
Scientific Basis of Professional Education 12
Summary and Conclusions 14

Chapter 2 Ethical Considerations in Clinical Research 17
by Sandra L. Alfano, PharmD, CIP, FASHP

Introduction 18
The Drug Development Process 18
Data and Safety Monitoring 21
Ethical Principles in Human Subjects Research 21
Respect for Persons 22
Beneficence 23
Justice 23
Regulatory Framework for Human Subjects Research 24
  Human Subject Research and Institutional Review Boards 25
  Data Confidentiality 26

Key Ethical Challenges in Clinical Research 27
Summary and Conclusions 29

Chapter 3  Research Design and Methods 32
by Rahul Khanna, PhD and Rajender R. Aparasu, MPharm, PhD, FAPhA

Introduction 33
Research Design 33
Causality 33
Research Design Classification 35
  Purpose 35
  Time Orientation 36
  Investigator Orientation 36

Clinical Research Designs 36
  Randomized Clinical Trials 37
  Observational Designs 37

Research Methodologies 39
  Reliability and Validity 39

Research Methods Classification 40
  Self-Reports 40
  Observation 42
  Biological Measures 43

Summary and Conclusions 43

Chapter 4  Randomized Controlled Trials 46
by Thomas C. Dowling, PharmD, PhD, FCCP

Introduction 47
Maximizing Validity 47
  Internal Validity 47
  External Validity 49

Minimizing Bias 50
  Investigator Bias 51
  Selection Bias 51
  Performance Bias 51
  Attrition Bias 51
  Detection Bias 52

Randomization 52
  Simple Randomization 52
  Block Randomization 52
  Stratified Randomization 52
  Adaptive Randomization 53

Blinding 53
  Single Blind 53
  Double Blind 53
  Triple Blind 54
  Open Label 54
<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample Size</td>
<td>54</td>
</tr>
<tr>
<td>Effect Size</td>
<td>54</td>
</tr>
<tr>
<td>Power</td>
<td>54</td>
</tr>
<tr>
<td>Research Protocol</td>
<td>55</td>
</tr>
<tr>
<td>Selecting the Participants</td>
<td>56</td>
</tr>
<tr>
<td>Target Population</td>
<td>56</td>
</tr>
<tr>
<td>Study Sample</td>
<td>56</td>
</tr>
<tr>
<td>Inclusion/Exclusion Criteria</td>
<td>56</td>
</tr>
<tr>
<td>Recruitment</td>
<td>56</td>
</tr>
<tr>
<td>Selection of Control Group</td>
<td>57</td>
</tr>
<tr>
<td>Placebo Concurrent Control</td>
<td>57</td>
</tr>
<tr>
<td>Active Controls</td>
<td>57</td>
</tr>
<tr>
<td>Historical (External) Controls</td>
<td>57</td>
</tr>
<tr>
<td>Non-Inferiority Trials</td>
<td>57</td>
</tr>
<tr>
<td>Study Design Description</td>
<td>58</td>
</tr>
<tr>
<td>Parallel</td>
<td>58</td>
</tr>
<tr>
<td>Crossover</td>
<td>58</td>
</tr>
<tr>
<td>Carryover and Washout</td>
<td>59</td>
</tr>
<tr>
<td>Factorial Design</td>
<td>59</td>
</tr>
<tr>
<td>Group or Cluster Randomization</td>
<td>59</td>
</tr>
<tr>
<td>Adaptive Design</td>
<td>59</td>
</tr>
<tr>
<td>Designing the Intervention</td>
<td>59</td>
</tr>
<tr>
<td>Effectiveness versus Efficacy</td>
<td>59</td>
</tr>
<tr>
<td>Safety</td>
<td>60</td>
</tr>
<tr>
<td>Adherence</td>
<td>60</td>
</tr>
<tr>
<td>Study Measurements</td>
<td>60</td>
</tr>
<tr>
<td>Baseline Measurement</td>
<td>60</td>
</tr>
<tr>
<td>Process Measurement</td>
<td>61</td>
</tr>
<tr>
<td>Outcome Measurement</td>
<td>61</td>
</tr>
<tr>
<td>Biomarkers</td>
<td>61</td>
</tr>
<tr>
<td>Safety Monitoring</td>
<td>61</td>
</tr>
<tr>
<td>Analyzing the Results</td>
<td>62</td>
</tr>
<tr>
<td>When to Analyze</td>
<td>62</td>
</tr>
<tr>
<td>How to Analyze</td>
<td>62</td>
</tr>
<tr>
<td>Analytical Approach</td>
<td>63</td>
</tr>
<tr>
<td>Relative Risk and Risk Difference</td>
<td>63</td>
</tr>
<tr>
<td>Number Needed to Treat</td>
<td>64</td>
</tr>
<tr>
<td>Strengths and Weaknesses</td>
<td>64</td>
</tr>
<tr>
<td>Summary and Conclusions</td>
<td>65</td>
</tr>
<tr>
<td>Chapter 5</td>
<td>67</td>
</tr>
<tr>
<td><strong>Cohort and Case-Control Studies</strong></td>
<td>68</td>
</tr>
<tr>
<td>by Lori A. Fischbach, MPH, PhD and</td>
<td></td>
</tr>
<tr>
<td>Bradley C. Martin, PharmD, PhD</td>
<td></td>
</tr>
<tr>
<td>Introduction</td>
<td>68</td>
</tr>
<tr>
<td>Cohort Studies</td>
<td>68</td>
</tr>
<tr>
<td>General Design Framework</td>
<td>68</td>
</tr>
<tr>
<td>Types of Cohort Designs</td>
<td>69</td>
</tr>
<tr>
<td>Exposure Evaluation</td>
<td>70</td>
</tr>
<tr>
<td>Outcome Evaluation</td>
<td>70</td>
</tr>
<tr>
<td>Analytic Framework for Cohort Studies</td>
<td>71</td>
</tr>
</tbody>
</table>
Case-Control Studies 74
- General Design Framework 74
- Selection of Cases and Controls 74
- Types of Case-Control Designs 76
- Defining Exposure Time Windows 76
- Analytic Framework for Case-Control Studies 76
- Confounder Adjustment 78

Advantages and Disadvantages of Cohort and Case-Control Designs 79
Data Sources for Case-Control and Cohort Studies 79
Biases and Approaches for Minimizing Biases in Epidemiologic Studies 80
Summary and Conclusions 83

Chapter 6 Other Observational Studies 86
by Joel F. Farley, PhD

Introduction 87

Cross-Sectional Studies 87
- Study Design 87
- Analysis 90
- Strengths and Limitations 90

Pre- and Post-Observational Study Designs 91
- Study Design 91
- Analysis 91
- Strengths and Limitations 92

Time Series Analysis 93
- Study Design 94
- Analysis 94
- Strengths and Weaknesses 95

Ecological Studies 96
- Study Design and Analysis 96
- Strengths and Weaknesses 96

Summary and Conclusions 97

Chapter 7 Case Reports and Case Series 99
by Jane R. Mort, PharmD and Olayinka O. Shiyanbola, PhD

Introduction 100

Case Reports 100
- Case Report Definition 100
- Case Report Type Based on Objectives 100
- Case Report Study Design and Write-Up 102
- Characteristics of a Good Case Report 103
- Case Report Strengths 104
- Case Report Limitations 105
- Critically Evaluating Case Reports 105

Case Series 106
- Case Series Definition 106
- Purpose of a Case Series 106
## Section 2  Statistical Principles and Data Analysis  112

### Chapter 8  Measurement and Descriptive Analysis  113

*by Karen Blumenschein, PharmD and Amie Goodin, MPP*

<table>
<thead>
<tr>
<th>Introduction</th>
<th>114</th>
</tr>
</thead>
<tbody>
<tr>
<td>Variable Classification Schemes</td>
<td>114</td>
</tr>
<tr>
<td>Levels of Measurement</td>
<td>115</td>
</tr>
<tr>
<td>The Conceptual Role of Variables in Research Questions</td>
<td>117</td>
</tr>
<tr>
<td>Measures of Central Tendency (Measures of Central Location)</td>
<td>117</td>
</tr>
<tr>
<td>Measures of Dispersion</td>
<td>118</td>
</tr>
<tr>
<td>Organizing and Visualizing Data</td>
<td>120</td>
</tr>
<tr>
<td>Commonly Encountered Proportions and Rates</td>
<td>124</td>
</tr>
<tr>
<td>Mortality and Morbidity Rates</td>
<td>124</td>
</tr>
<tr>
<td>Incidence</td>
<td>125</td>
</tr>
<tr>
<td>Prevalence</td>
<td>125</td>
</tr>
<tr>
<td>Diagnostic Tests</td>
<td>125</td>
</tr>
<tr>
<td>Performance Measures for Diagnostic Tests</td>
<td>126</td>
</tr>
<tr>
<td>Receiver Operating Characteristic (ROC) Curves</td>
<td>128</td>
</tr>
<tr>
<td>Summary of Diagnostic Tests</td>
<td>129</td>
</tr>
</tbody>
</table>

| Summary and Conclusions | 129 |

### Chapter 9  Interpretation and Basic Statistical Concepts  132

*by Spencer E. Harpe, PharmD, PhD, MPH*

<table>
<thead>
<tr>
<th>Introduction</th>
<th>133</th>
</tr>
</thead>
<tbody>
<tr>
<td>Statistical Distributions and the Central Limit Theorem</td>
<td>133</td>
</tr>
<tr>
<td>Normal Distribution</td>
<td>133</td>
</tr>
<tr>
<td>Binomial Distribution</td>
<td>135</td>
</tr>
<tr>
<td>Other Distributions</td>
<td>135</td>
</tr>
<tr>
<td>Central Limit Theorem</td>
<td>136</td>
</tr>
<tr>
<td>Statistical Inference</td>
<td>137</td>
</tr>
<tr>
<td>Definition of Statistical Inference</td>
<td>137</td>
</tr>
<tr>
<td>Populations and Samples</td>
<td>137</td>
</tr>
<tr>
<td>Mechanisms of Inference</td>
<td>138</td>
</tr>
<tr>
<td>Statistical Estimation</td>
<td>138</td>
</tr>
<tr>
<td>Point Estimation</td>
<td>138</td>
</tr>
<tr>
<td>Interval Estimation</td>
<td>138</td>
</tr>
<tr>
<td>Interpretation and Importance of the Confidence Interval</td>
<td>140</td>
</tr>
<tr>
<td>Hypothesis Testing</td>
<td>141</td>
</tr>
<tr>
<td>Characteristics of Hypotheses</td>
<td>141</td>
</tr>
<tr>
<td>Types of Hypotheses</td>
<td>141</td>
</tr>
<tr>
<td>Errors in Hypothesis Testing</td>
<td>141</td>
</tr>
</tbody>
</table>
Contents

Types of Hypothesis Tests 143
  Non-Directional Tests 143
  Directional Tests 146
Process of Performing a Hypothesis Test 147
  Traditional Approach 148
  Confidence Interval Approach 150
What “Significant” Means 151
  Statistical Significance 151
  Clinical Significance 152
Summary and Conclusions 152

Chapter 10 Bivariate Analysis and Comparing Groups 155
by Marion K. Slack, PhD and Bismark Baidoo, PhD

Introduction 156
Case Scenario 156
Continuous Outcome: Comparing Two Groups Using the t-test 157
ANOVA for Three or More Groups 159
Categorical Outcome: Comparing Two Groups Using the Chi-Square Test of Homogeneity 160
Independent versus Dependent Groups: The Paired t-test 162
Alternative Approaches for Comparing Groups 164
  The Sign Test 164
  The Wilcoxon–Mann–Whitney Test 165
  The Kruskal–Wallis Test 166
The Concept of Correlation 167
  The Pearson Correlation Coefficient 168
  The Spearman Rank Correlation Coefficient 170
  A Final Note on Correlation 172
Using a Flowchart to Identify the Appropriate Statistical Test for Comparing Groups 172
Summary and Conclusions 174

Chapter 11 Simple and Multiple Linear Regression 176
by Dan Friesner, PhD and John P. Bentley, PhD

Introduction 177
Case Scenario 177
Omitted Variables, Confounders, Bias, and Efficiency 179
Simple Linear Regression 181
Multiple Linear Regression 185
  General Features 185
  Dummy Variables 189
  Effect Modification 190
  Multiple Linear Regression Example from the Literature 191
Summary and Conclusions 192
Chapter 12  Logistic Regression and Survival Analysis  195
   by John P. Bentley, PhD and Dan Friesner, PhD

   Introduction  196
   Binary Logistic Regression  196
   Survival Analysis  202
      General Features  202
      The Kaplan–Meier Method  202
      The Cox Proportional Hazards Regression Model  204
   Summary and Conclusions  206

Chapter 13  Sample Size and Power Analysis  208
   by John P. Bentley, PhD

   Introduction  209
   Cases from the Literature  209
   General Concepts  210
   Information Necessary to Compute Sample Size  211
      Using Power Analysis  211
         Type of Data  212
         Type of Hypothesis Test  212
         Measure of Precision (or Variance)  213
         Magnitude of Effect  213
         Specified Significance Level  214
         Target Level of Power  214
   Some Available Software  214
   Worked Examples  215
      Comparing Two Groups—Continuous Response  215
      Comparing Two Groups—Dichotomous Response  216
      Test for Non-inferiority: Comparing Two Groups on a
      Dichotomous Response  218
      Comparing Three or More Groups—Continuous Response  219
   Other Considerations and Issues  221
      Case-Control and Cohort Studies  221
      Determining Variance  222
      Sample Size Estimation for More Complex Analyses  222
      Retrospective Power Analysis  223
      Sample Size Planning Using Precision Analysis  223
   Summary and Conclusions  224

Chapter 14  Systematic Review and Meta-Analysis  227
   by Richard A. Hansen, RPh, PhD

   Introduction  228
   Systematic Review  228
   Meta-Analysis  233
      Continuous Outcome Example  234
      Dichotomous Outcome Example  236
   Summary and Conclusions  239
Section 3 Principles of Drug Literature Evaluation

Chapter 15 Principles of Evidence-Based Medicine
by Jeffrey T. Sherer, PharmD, MPH, BCPS

Introduction
History and Evolution of EBM
EBM Today
Steps in Practicing EBM
  Asking an Answerable Question
  Finding Evidence
  Appraising Evidence
  Applying Evidence
Advantages of EBM
Limitations of EBM
Role of the Pharmacist in EBM
Summary and Conclusions

Chapter 16 Introduction to Drug Literature
by McKenzie C. Ferguson, PharmD, BCPS and
Erin M. Timpe Behnen, PharmD, BCPS

Introduction
Systematic Approach to Drug Information Requests
Quality of Medical Literature
Types of Literature
  Tertiary Literature
  Advantages and Disadvantages of Tertiary Literature
  Secondary Literature
  Advantages and Disadvantages of Secondary Literature
  Primary Literature
  Evaluation of Primary Literature
  Advantages and Disadvantages of Primary Literature
Information Cycle
Drug Literature on the Internet
  Search Engines
  Evaluation
Summary and Conclusions

Chapter 17 Evaluating Clinical Literature: An Overview
by Jill T. Johnson, PharmD, BCPS

Introduction
General Format of an Article
  Abstract
  Introduction
  Methods
  Results
  Discussion
  References
Critically Appraising a Research Article 277
1. Is This a Clinically Relevant Research Study? 278
2. Is the Study Design Appropriate to Address the Research Question? 278
3. Are the Recruitment and Selection of the Study Sample Explained Clearly? 279
4. Are the Study Methods Appropriately Explained? 280
5. Are the Endpoints Relevant for Patient Care? 281
6. Are the Statistical Analyses Appropriate for the Study? 283
7. What are the Key Research Findings? 284
8. Are There any Study Limitations? 285
9. How can the Research Findings be Used in Practice? 286

General Considerations 286
1. Is This a Peer-Reviewed Paper? 287
2. Who Funded the Research? 287
3. Are There any Conflicts of Interests? 287

Summary and Conclusions 288

Chapter 18 Evaluating Randomized Controlled Trials 290
by Erin M. Timpe Behnen, PharmD, BCPS and McKenzie C. Ferguson, PharmD, BCPS

Introduction 291
Criteria for Evaluating and Reporting Clinical Trials 291
Standardized Reporting Requirements 291
Quality Assessment Scales for Randomized Trials 294

Validity 294
Internal Validity 295
External Validity 296

Critically Evaluating Randomized Controlled Trials 296
Study Sample 298
Randomization and Blinding 299
Intervention and Control Group 299
Clinical Endpoints 300
Trial Findings 301
Limitations and Implications 302

Application to Clinical Practice 303
Summary and Conclusions 304

Chapter 19 Evaluating Observational Studies 307
by Chenghui Li, PhD

Introduction 308
Bias and Confounding 308
Bias 308
Confounding 309

General Criteria for Evaluating Observational Studies 309
Research Question 311
Study Design 311
Subject Selection 312
Exposure and Outcome Measures 314
## CONTENTS

Data Analysis and Confounding 316  
Presentation of Results and Interpretation 318  
Application to Practice and Policy 318  
Comparison of Results from Observational Studies and Randomized Trials 319  
Summary and Conclusions 320

### Chapter 20 Applying Drug Literature to Patient Care 323

*by Katy E. Trinkley, PharmD and Steven M. Smith, PharmD, MPH*

Introduction 324  
General Principles of Applying Evidence to Patient Care 324  
Application of Clinical Trial Results to Patient Care 325  
Application of Practice Guidelines to Patient Care 327  
Staying Up with Drug Information 330  
Other Approaches 334  
Summary and Conclusions 334

### Chapter 21 Basics of Journal Club 336

*by Catherine L. Hatfield, PharmD*

Introduction 337  
Definition and Purpose of Journal Clubs 337  
Format of Journal Clubs 338  
Types 338  
Focus 339  
Article Selection 340  
Preparation 341  
Timing 341  
Presentation 341  
Leadership 341  
Presenter 341  
Environment 342  
Audience 342  
Feedback 342  
Characteristics of Effective Journal Clubs 343  
Critical Appraisal Tools for Journal Clubs 344  
Summary and Conclusions 344

Appendix 347  
Glossary 350  
Index 362
With the increasing emphasis on evidence-based practices, there is a greater need for pharmacists to understand clinical research, evaluate scientific findings, and translate evidence to support patient-care decisions. This requires a comprehensive understanding of the principles and practice of drug literature evaluation with a strong grounding in research design and statistical methods. Most available texts emphasize statistical approaches and/or scientific literature evaluation techniques. Although there may be comprehensive books in other health professions, it is challenging to find a pharmacy textbook that covers all critical research design and evaluation elements to translate evidence into practice. We decided to edit this book to provide a balanced approach to the principles of clinical research and statistics for evaluating pharmacy literature to implement evidence-based pharmacotherapy.

Most pharmacy schools offer a course in the pharmacy professional program that covers fundamentals of research design, biostatistics, and evaluation of pharmacy literature, as required by the Accreditation Council for Pharmacy Education (ACPE). Consequently, this book is divided into three sections to provide comprehensive course content to meet and exceed these curriculum standards set by the ACPE. Section 1 of the book covers principles of scientific research with an emphasis on clinical research designs ranging from randomized controlled trials to case reports. Section 2 of the book provides the foundation necessary to understand statistics and to critically evaluate results from statistical analyses reported in the medical literature with a focus on common statistical methods. Section 3 of the book covers principles of evidence-based medicine, drug literature sources and evaluation techniques, and application of evidence to patient care. There are seven chapters in each section of the book.

Chapter 1 defines basic, applied, clinical, and translational research, and describes the steps in scientific research and evidence-based medicine. Chapter 2 explains the guiding ethical principles in clinical research and discusses the regulatory framework governing clinical research. Chapter 3 provides the basics of designing clinical research, with an emphasis on common clinical research designs and methodologies. Chapter 4 discusses the design considerations associated with randomized controlled trials, including common clinical designs and analytical framework. Chapters 5 and 6 provide observational approaches for conducting clinical research. Chapter 5 describes case-control and cohort designs and includes a discussion of common biases and analytical approaches to minimize such biases. Chapter 6 provides an overview of cross-sectional studies, pre- and post-observational studies, ecological studies, and time series evaluations. Chapter 7 presents the key steps in designing a case report and case series studies along with tools to critically evaluate these designs.
Chapter 8 discusses the summarizing, organizing, and presenting functions of statistics, commonly referred to as descriptive statistics, and also introduces the different kinds of data that are collected in clinical research. Chapter 9 provides the general foundation for applying basic tools of statistical inference, focusing on the related mechanisms of estimation and hypothesis testing. Given that many studies in the drug literature involve the comparison of two or more groups, Chapter 10 discusses commonly used statistical procedures that are used to answer research questions involving group comparisons; in addition, it describes statistical methods for assessing the correlation between two variables. Chapters 11 and 12 provide an overview of regression analysis methods that can be used to account and/or adjust for variables that cannot be handled at the design stage of an experiment. Chapter 11 describes simple linear and multiple regression approaches to address a number of research problems, such as confounding and effect modification. Chapter 12 introduces logistic regression and Cox regression methods to analyze binary and time-to-event outcomes, respectively. Chapter 13 introduces the statistical principles underlying sample size calculation. Chapter 14 presents the elements of the systematic review process and describes meta-analysis as a method to quantitatively synthesize evidence from studies identified in a systematic review.

Chapter 15 identifies the steps involved in evidence-based medicine along with the discussion of its strengths and limitations. Chapter 16 discusses the sources and use of primary, secondary, and tertiary literature to identify clinical evidence for evidence-based medicine. Chapters 17, 18, and 19 discuss approaches to assess published primary literature for patient care. Chapter 17 provides a stepwise approach to assess published literature with an emphasis on evaluating the study objectives, methods and design, statistics, results, and discussion. Chapter 18 describes the key considerations for evaluating methodological rigor in randomized controlled trials using an example. Chapter 19 describes and applies formal criteria to evaluate observational studies using an example. Chapter 20 discusses general principles of applying evidence to patient care with an emphasis on evidence from clinical trials and practice guidelines. Finally, Chapter 21 describes the general format of a journal club and examines the characteristics of an effective journal club.

This book is designed for professional pharmacy (PharmD) students. Instructors teaching principles of research and drug literature evaluation can design the professional course primarily based on this book or can supplement this book with research articles. The contents of the book can be delivered in one or two semesters. Chapters were written by expert authors specializing in pharmacy practice and research. Each chapter includes the following elements:

- **Learning Objectives** present the chapter’s desired outcomes to the reader.
- **Key Terminology** helps the reader quickly identify critical new terms.
- **Review Questions** allow readers to apply what has been learned in the chapter and assess their understanding of the content.
- **Online Resources** direct students to web sites relevant to the content.

The chapters are designed to provide the knowledge base and application techniques for research design and drug literature evaluation. In addition to figures and tables, numerous pharmacy examples and case studies are provided to aid student learning. Additional readings from pharmacy journals and a drug literature evaluation project can improve the critical thinking skills of pharmacy students. The online sources and chapter references can be used to supplement the content. This book can also be an excellent resource for students in residency and fellowship training programs. In addition, this
book can be beneficial to pharmacy practitioners and professionals, especially those involved in training students, residents, and fellows.

We would greatly appreciate feedback from students and faculty for future editions. All knowledge is considered as work in progress, including the contents of this book.

Rajender R. Aparasu, MPharm, PhD, FAPhA
John P. Bentley, RPh, PhD, FAPhA

INSTRUCTOR RESOURCES

Qualified instructors can receive the full suite of Instructor Resources, including the following:

• PowerPoint Presentations, featuring more than 600 slides
• Test Bank, containing more than 300 questions
• Answer Key, including answers for the end-of-chapter Review Questions

To gain access to these valuable teaching materials, contact your Health Professions Account Specialist at http://go.jblearning.com/findarep.

STUDENT RESOURCES

The Navigate Companion Website features numerous study aids and learning tools to help students get the most out of their course and prepare for class, including:

• Interactive Glossary
• Crossword Puzzles
• Interactive Flashcards
• Matching Questions
• Web Links
FOREWORD

When Drs. Aparasu and Bentley asked me to write the foreword for this book, I hesitated. It took me a long while to finally agree. I hesitated because a book’s foreword is supposed to be written by someone famous who tells the readers why the authors are qualified to write the book and why the book is important. I hesitated because I could only fulfill two of the three conditions by writing the foreword to this book: the editors are eminently qualified and it is an important contribution to the library of students and practitioners. Both of the editors are seasoned, knowledgeable, and experienced with decades of direct involvement in evidence-based research. More importantly, they have convinced a veritable “who’s who” of clinical trial, health services, and comparative effectiveness researchers and drug information experts to share their expertise, insights, and pearls of wisdom.

Second, why is this book important? Dr. Bentley and I served together on the editorial staff of the *Journal of the American Pharmacists Association (JAPhA)* for years. During our time together, we had innumerable discussions about the importance of study design and statistical methods to the appropriate interpretation and clinical application of research findings. Through these often lengthy discussions—discussions that we had more than once because they are difficult issues to resolve when interpreting a study’s findings and conclusions—we came to understand the power of the statement “every study has limitations based on its design and statistical methods.” It became abundantly clear to us that while these limitations are generally listed in a specific section designed for that purpose in most articles, the implications of those limitations are not. What does this statement mean? Let me provide an example to illustrate.

While a research article might list “confounding by severity” as a potential study limitation in an observational study, what are the implications of that bias for someone trying to use the information contained in the article in their practice? What cautions should the practitioner exercise in interpreting and adopting the researcher’s conclusions into their personal practice? Should an author present the implications of various decisions a practitioner could make based on the limitations? Should the practitioner suddenly stop prescribing beta-agonist medications because a study found a greater risk of asthma-related deaths with increasing beta-agonist use? Should the practitioner deny additional use of the medication after a certain point? What are the implications of stopping or reducing the use of rescue inhalers among severely ill asthmatics? Disease severity is a potential confounder in observational studies. Severely ill patients need their rescue inhalers more frequently because their asthma is uncontrolled and, even then, they cannot all be rescued unless the underlying reason for life threatening asthma is directly addressed. This book was designed to provide and encourage practitioner’s development and use of critical drug information evaluation skills through a deeper understanding of
the foundational principles of study design and statistical methods. Because guidance on how a study’s limited findings should not be used is rare, practitioners must understand and evaluate for themselves the veracity and implications of the inherently limited primary literature findings they use as sources of drug information to make evidence-based decisions together with their patients.

The editors organized the book into three supporting sections to meet their pedagogical goals and address practitioners’ needs in translating research into practice. Section 1 is titled “Principles of Clinical Research.” After a discussion of the scientific method and ethical considerations associated with research, Section 1 examines the strengths, weaknesses, and implications of major experimental and nonexperimental (e.g., observational) study designs. Section 2, “Statistical Principles and Data Analysis,” introduces the reader to the principles of statistical methods, data analysis, and the interpretation of statistical results, including power analysis and systematic reviews. Finally, Section 3, “Principles of Drug Literature Evaluation,” introduces the reader to the principles of drug literature evaluation. From the perspective of a former editor-in-chief of a pharmacy professional journal, Section 3 provides the most important applications for translating research into practice. Section 3 provides the reader with the skills needed to evaluate studies ranging from randomized controlled trials to observational studies. It facilitates the application of the information contained in these studies. Furthermore, it assists readers in their attempts to apply information from these studies, with their limitations, to support pharmacy practice and patient-care decisions—applications that are commonly lacking with simple lists of the study’s limitations. Although Section 3 is the heart of the book, it cannot survive without the study design and statistical methods foundations.

Sometimes, the difference between a foreword and a book review gets blurred—even to the writer. However, one primer on writing a book foreword that I consulted stated “…in the conclusion, remind the readers why you are writing the foreword and why it matters.” As health professionals, we are tasked with protecting the lives of our patients; it is our sine qua non. Unfortunately, as multiple examples in this book and the literature point out, published research is not without its shortcomings and failings. Therefore, as health professionals we must be able to evaluate the strengths, weaknesses, and implications of the evidence, both new and not-so-new, for ourselves. There is no such thing as the perfect study. As health professionals, we cannot simply rely on the lists and conclusions of others; we must be prepared to make decisions based on the scientific evidence for ourselves. Thanks to the editors, authors, and content of this book, you can now be more prepared than ever for translating research into practice.

L. Douglas Ried, PhD, FAPhA
Editor-in-Chief Emeritus
Journal of the American Pharmacists Association
Professor and Associate Dean for Academic Affairs
College of Pharmacy
University of Texas at Tyler
Tyler, Texas
ACKNOWLEDGEMENTS

Many individuals have contributed to the fruition of this book. The concepts and vision for this book have evolved over 18 years of teaching professional courses in research design, biostatistics, and drug literature evaluation. Feedback from pharmacy students and regular discussions with colleagues, especially Dr. Rebecca Baer at South Dakota State University (Aparasu) and Dr. Kim Adcock at the University of Mississippi (Bentley), were instrumental in developing the master plan for this book. Sincere thanks to all of the authors for patiently working with us in developing the chapter content and for contributing their expertise to this project. The feedback from the reviewers was very helpful in improving the content and formatting of the book. The insight and support of Dr. Albert Wertheimer was instrumental in undertaking this book.

We greatly appreciate Dr. Jeffrey Sherer for helping us recruit the authors for the third section of the book and overseeing the development of initial chapter outlines. Our gratitude also goes to several of our graduate students, who offered input from a student’s perspective on several chapters. We also would like to thank our respective university and college/school faculty colleagues and administration teams for providing us the time and encouragement to complete this project. Finally, we are grateful to the publishing team, both past and present, at Jones & Bartlett Learning, especially Katey Birtcher, Teresa Reilly, and Sean Fabery, for their help and support. The editorial assistance of the production staff at Jones & Bartlett Learning, especially Tina Chen, is also very much appreciated.

Rajender R. Aparasu, MPharm, PhD, FAPhA
John P. Bentley, RPh, PhD, FAPhA
ABOUT THE EDITORS

Rajender R. Aparasu, MPharm, PhD, FAPhA, is a Professor and Chair of the Department of Pharmaceutical Health Outcomes and Policy at the University of Houston College of Pharmacy. He has more than 18 years of experience in teaching and research in the area of pharmaceutical practice and policy. He has taught various professional and graduate courses in colleges of pharmacy. Dr. Aparasu is a recognized educational leader and researcher in pharmaceutical practice and policy. He was instrumental in the growth of graduate programs at the University of Houston to train the next generation of pharmacy leaders. He led the creation of one of the largest MS/Residency programs in the country in collaboration with six Texas Medical Center institutions in Houston. He has served on patient safety and medication therapy management task forces.

Dr. Aparasu has received several federal and non-federal grants to address a broad array of quality of pharmaceutical care issues, especially among the elderly. He is a peer-reviewer for numerous pharmacy and medical journals and has more than 100 presentations in national/international meetings and more than 70 peer-reviewed publications. He serves on the editorial boards of several pharmacy and healthcare journals, and has been recognized as an Exceptional Peer Reviewer by several journals. Dr. Aparasu is a grant reviewer for the American Heart Association (AHA) and the Patient-Centered Outcomes Research Institute (PCORI). He is an Associate Editor of BMC Geriatrics and has edited a book for graduate students titled Research Methods for Pharmaceutical Practice and Policy. He was recognized by his peers as a 2012 Fellow of the American Pharmacists Association for his exemplary professional achievements in practice and outstanding service to the profession.

John P. Bentley, RPh, PhD, FAPhA, is a Professor of Pharmacy Administration and a Research Professor in the Research Institute of Pharmaceutical Sciences at The University of Mississippi School of Pharmacy. In the professional pharmacy curriculum, Dr. Bentley teaches elements of research design, biostatistics, epidemiology, and drug literature evaluation. At the graduate level, he teaches several applied statistics courses, including general linear models, multivariate statistics, and elective courses focusing on the application of modern longitudinal data analysis methods and principles of statistical mediation and moderation. He has conducted research projects in a variety of areas, including quality of life; medication adherence; medication use, misuse, and outcomes; pharmaceutical marketing and patient behavior; patients’ evaluation of health-care providers; pharmacy practice management; tobacco use, control, and cessation among college students; and ethics and professionalism. His statistics research interests include statistical mediation analysis and longitudinal data analysis.
Dr. Bentley has worked as a member of a number of interdisciplinary research teams and has consulted with numerous researchers concerning statistical analysis. In 2009, he was named a Fellow of the American Pharmacists Association and has been recognized as a Thelma Cerniglia Distinguished Teaching Scholar at The University of Mississippi School of Pharmacy. He has served as a peer reviewer for a number of journals and as an Associate Editor for the *Journal of the American Pharmacists Association*. Dr. Bentley received his BS in pharmacy and MBA from Drake University, his MS and PhD in pharmacy administration from The University of Mississippi, and his MS and PhD in biostatistics from The University of Alabama at Birmingham (UAB).
CONTRIBUTORS

Sandra L. Alfano, PharmD, FASHP, CIP
Research Scientist, General Internal Medicine
Chair, Human Investigation Committee I and III
Co-Chair, Embryonic Stem Cell Research Oversight Committee
Yale University
New Haven, Connecticut

Bismark Baidoo, PhD
Research Associate
Department of Pharmacy Practice and Science
College of Pharmacy
The University of Arizona
Tucson, Arizona

Karen Blumenschein, PharmD
Associate Professor, Pharmacy Practice and Science Department
Associate Professor, Martin School of Public Policy and Administration
College of Pharmacy
University of Kentucky
Lexington, Kentucky

Thomas C. Dowling, PharmD, PhD, FCCP
Associate Professor and Vice Chair
Department of Pharmacy Practice and Science
School of Pharmacy
University of Maryland
Baltimore, Maryland

Joel F. Farley, PhD
Associate Professor
Division of Pharmaceutical Outcomes and Policy
Eshelman School of Pharmacy
University of North Carolina
Chapel Hill, North Carolina
Contributors

McKenzie C. Ferguson, PharmD, BCPS
Assistant Professor
Department of Pharmacy Practice
Southern Illinois University Edwardsville
Edwardsville, Illinois

Lori A. Fischbach, PhD, MPH
Associate Professor
Department of Epidemiology
Fay W. Boozman College of Public Health
University of Arkansas for Medical Sciences
Little Rock, Arkansas

Daniel L. Friesner, PhD
Professor of Pharmacy Practice &
Associate Dean for Student Affairs and Faculty Development
College of Pharmacy, Nursing, and Allied Sciences
North Dakota State University
Fargo, North Dakota

Amie Goodin, MPP
Research Administrative Coordinator
Institute for Pharmaceutical Outcomes and Policy
University of Kentucky
Lexington, Kentucky

Richard A. Hansen, PhD
Gilliland Professor and Head
Department of Health Outcomes Research and Policy
Harrison School of Pharmacy
Auburn University
Auburn, Alabama

Spencer E. Harpe, PharmD, PhD, MPH
Associate Professor of Pharmacy Practice
Chicago College of Pharmacy
Midwestern University
Downers Grove, Illinois

Catherine L. Hatfield, PharmD
Clinical Associate Professor
Director, Introductory Pharmacy Practice Experiences
Department of Clinical Sciences and Administration
College of Pharmacy
University of Houston
Houston, Texas
Jill T. Johnson, PharmD, BCPS
Associate Professor
Department of Pharmacy Practice
College of Pharmacy
University of Arkansas for Medical Sciences
Little Rock, Arkansas

Rahul Khanna, PhD
Assistant Professor of Pharmacy Administration
Research Assistant Professor in the Research Institute of Pharmaceutical Sciences
School of Pharmacy
University of Mississippi
Oxford, Mississippi

Chenghui Li, PhD
Assistant Professor
Division of Pharmaceutical Evaluation and Policy
College of Pharmacy
University of Arkansas for Medical Sciences
Little Rock, Arkansas

Bradley C. Martin, PharmD, PhD
Professor and Division Head
Division of Pharmaceutical Evaluation and Policy
College of Pharmacy
University of Arkansas for Medical Sciences
Little Rock, Arkansas

Jane R. Mort, PharmD
Professor of Pharmacy Practice
Associate Dean for Academic Programs
College of Pharmacy
South Dakota State University
Brookings, South Dakota

Jeffrey T. Sherer, PharmD, MPH, BCPS
Clinical Associate Professor
Department of Clinical Sciences and Administration
College of Pharmacy
Texas Medical Center Campus
Houston, Texas

Olayinka O. Shiyanbola, PhD
Assistant Professor of Social and Administrative Sciences
School of Pharmacy
University of Wisconsin-Madison
Madison, Wisconsin
xxviii CONTRIBUTORS

Marion K. Slack, PhD
Professor
Department of Pharmacy Practice and Science
College of Pharmacy
The University of Arizona
Tucson, Arizona

Steven M. Smith, PharmD, MPH
Assistant Professor
Departments of Pharmacotherapy & Translational Research and Community Health
Colleges of Pharmacy and Medicine
University of Florida
Gainesville, Florida

Erin M. Timpe Behnen, PharmD, BCPS
Associate Professor of Pharmacy Practice
Director, Drug Information & Wellness Center
Southern Illinois University Edwardsville
Edwardsville, Illinois

Katy E. Trinkley, PharmD
Assistant Professor, Department of Clinical Pharmacy
Skaggs School of Pharmacy and Pharmaceutical Sciences
University of Colorado
Aurora, Colorado
REVIEWERS

Joyce Addo-Atuah, PhD
Assistant Professor of Pharmacy & Health Outcomes
College of Pharmacy
Touro College
New York City, New York

Miriam A. Ansong, RPh, EMBA, PharmD
Director, Center for Global Health Education and Resources
Associate Professor of Pharmacy Practice
School of Pharmacy
Cedarville University
Cedarville, Ohio

Aleda M. H. Chen, PharmD, MS, PhD
Assistant Professor of Pharmacy Practice
School of Pharmacy
Cedarville University
Cedarville, Ohio

Chad A. Knoderer, PharmD
Associate Professor of Pharmacy Practice
College of Pharmacy and Health Sciences
Butler University
Indianapolis, Indiana

Anandi V. Law, BPharm, MS, PhD, FAACP, FAPhA
Professor and Chair
Department of Pharmacy Practice and Administration
College of Pharmacy
Western University of Health Sciences
Pomona, California

Quang A. Le, PharmD, PhD
Assistant Professor
College of Pharmacy
Western University of Health Sciences
Pomona, California
William W. McCloskey, BA, BS, PharmD, RPh
Professor and Vice-Chair
Department of Pharmacy Practice
School of Pharmacy
MCPHS University
Boston, Massachusetts

Leslie Ochs, PharmD, PhD, MSPH
Assistant Professor, Department of Pharmacy Practice
School of Pharmacy
University of New England
Portland, Maine

Robin Pucci, PharmD
Director, Laboratory and Patient Care
Clinical Assistant Professor of Pharmacy Practice
School of Pharmacy
Fairleigh Dickinson University
Florham Park, New Jersey

Jonathan H. Watanabe, PharmD, PhD
Assistant Professor
College of Pharmacy
Western University of Health Sciences
Pomona, California